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Breast Tumor Kinase (Brk) 
Historical Background 
The intracellular protein tyrosine kinase, PTK6 (also known as the breast tumor kinase, Brk), has been 
implicated in the development and progression of a number of different tumor types. First identified in 3 
separate studies in the early 1990s, it was initially found in a study to determine which tyrosine kinases 
were expressed in human melanocytes and then the full-length sequence was subsequently cloned from 
metastatic breast cancer using a screen to identify novel kinases that were expressed in tumors, but not 
normal breast tissue. Identification of the murine orthologue, sik, in mouse intestinal cells was achieved 
by the generation of a library of kinase catalytic domains. 
PTK6 is related to the Src family of protein kinases and belongs to a distinct class of enzymes which 
includes Frk and SRMS (reviewed Harvey and Burmi 2011) and expression produces two different 
isoforms as a result of alternative splicing (reviewed in Hussain and Harvey 2014) (Figure 1).  
 
Figure 1 –– PTK6 Figure 1.tif 
Figure 1: PTK6 domain structure. Schematic representation of the PTK6 gene structure and its 
products. All 8 exons are contained in the PTK6 transcript, resulting in production of a full length, fully 
functional protein. ALT-PTK6 arises as a result of alternative splicing, excluding exon 2. The subsequent 
protein shares the amino-terminus and the SH3 domain with its full length isoform and a frameshift 
results in the carboxy-terminus being truncated and proline rich (PR) 
 
Under normal physiological conditions, PTK6 expression is highly controlled and is usually limited to 
differentiating cells of epithelial origin. Several studies have reported that, pathologically (i.e. in disease 
tissue), PTK6 expression is increased in a number of different cancers compared to normal cells of the 
same tissue type (reviewed in Harvey and Burmi 2011). 
The apparent disparity in PTK6 expression and the difference in proliferation status between cellular 
differentiation in normal tissues, where cells tend not be dividing; and the fact that tumors are highly 
proliferative (and cells are dividing rapidly) makes PTK6 an intriguing molecule for study, as there are 
likely to be both context and function-specific differences that could be exploited in the development of 
anti-tumor therapies which conferring benefit to patients.  
Cellular Localization 
PTK6 has been reported to have different functions in different tissue types; for example, in normal 
tissues PTK6’s role appears to be related to regulating the differentiation process, whereas in tumors 
PTK6 promotes proliferation and cell survival. Variations in cellular localization are thought to be 
associated with PTK6’s opposing roles in both differentiation and proliferation. Altered cellular 
localization will no doubt affect the variety of substrates and binding partners that are available for PTK6, 
thereby contributing to the different functions/effects that have been ascribed to PTK6 expression. 
Myristoylation is a post- or co-translational protein modification, whereby a fatty acid-derived group is 
attached to an N-terminal amino acid. Such modifications allow proteins to associate with membrane 
structures. Although PTK6 is structurally related to Src, it lacks the amino-terminal myristoylation site 
(Mitchell et al. 1994). Without a myristoylation site, PTK6 is not able to associate directly with the 
plasma membrane, and therefore cellular localization is not tightly regulated. Originally PTK6 was 
thought to be solely a cytoplasmic kinase, however, it is now known to be in different cellular 
compartments, including at the membrane via association with its binding partners as well as in the 
nucleus. Association of a protein to the plasma membrane can be mimicked by experimental inclusion of 
a myristoylation site. Adding a myristoylation site to the N-terminus, enhanced PTK6’s oncogenic role by 
promoting cell proliferation, survival and migration of human embryonic kidney cells. Trapping PTK6 in 
the nucleus with synthetic nuclear localization signal abrogated these effects (Kim and Lee 2009); these 
in vitro experimental effects are supported by evidence from human tumors demonstrating that normal 
prostate epithelial cells and well-differentiated prostate carcinomas had nuclear PTK6, whereas as poorly 
differentiated prostate cancers were found to have cytoplasmic PTK6 (reviewed in Goel and Lukong 
2015). Increased expression of ALT-PTK6 resulted in an increase of constitutively active PTK6 in the 
nuclei of prostate tumor cells, suppressing proliferation (Brauer et al. 2011). Collectively, these studies 
suggest that PTK6’s oncogenic role may be dependent on its cellular localization; however, .as PTK6 
contains neither myristoylation sites nor nuclear localization signals, it is unclear how PTK6 delocalizes 
from one sub-cellular compartment to another and precisely which cellular signals are controlling this 
transition.  
PTK6 Substrates and Binding Partners 
As a tyrosine kinase with amino acid sequence homology to Src, PTK6 also has a similar domain 
structure consisting of SH2 and SH3 domains (which typically interact with phosphorylated tyrosines and 
proline-rich sequences respectively) as well as a kinase domain (which phosphorylates its target 
substrates on tyrosine). It is therefore capable of phosphorylating a number of target molecules and there 
is a rapidly expanding list of known interacting proteins (summarized in Table 1). To date, over 35 PTK6-
associated interactions have been identified (reviewed in Goel and Lukong 2015), but whether all of these 
interactions result in phosphorylation has not yet been determined. PTK6 is proposed to have some kinase 
independent function (reviewed Harvey and Burmi 2011)), suggesting that a functional kinase domain is 
not required for all of PTK6’s activities. It has been suggested that it may function as an adaptor 
molecule, and therefore it is highly likely that not all the interacting proteins will be substrates of PTK6’s 
kinase activity. Therefore it is possible that one of PTK6’s functions is to stabilize signaling complexes to 
allow phosphorylation of some of its interacting proteins and/or additional molecules within the complex 
by other kinases. This association in a large signaling complex, as an adaptor or scaffolding molecule, 
may also contribute to PTK6’s cellular localization. 






























































Table 1: Summary of the localization of the major identified PTK6-interacting proteins (see Goel and 
Lukong 2015 for a comprehensive review of the biological outputs of these interactions) . A further two 
substrates have been reported; however the proteins involved (which are 23 kDa and 100 kDa in size) 
have yet to be identified.  
* These proteins are reported to have functions in different cellular compartments, however it has not yet 
been determined whether PTK6 affects the function of these proteins in all their localizations.  
PTK6 and Signaling Pathways 
From the wide variety of substrates and interacting proteins that have already been identified (Table 1), it 
is clear that PTK6 plays a role in a number of different cellular processes and signaling pathways (Figure 
1). This is also apparent from the range of signaling molecules that activate PTK6, which include 
epidermal growth factor (EGF), Heregulin (HRG), insulin-like growth factor (IGF), Hepatocyte growth 
factor (HGF), osteopontin (OPN) and calcium ions. 
PTK6 has been shown to associate with all members of the ErbB receptor family (reviewed in Hussain 
and Harvey 2014) and potentiates the proliferative effects of EGF by activating the phosphoinositide 3-
kinase (PI3-K)/Akt signaling pathway. PTK6 is known to play a role in cell migration through the 
phosphorylation of paxillin, which is a ‘molecular scaffold’ that interacts with signaling molecules and a 
number of proteins that are involved in cell motility. In response to EGF, activated PTK6 phosphorylates 
paxillin resulting in the activation of Rac1 and an increase in cell migration. Treatment of breast cancer 
cells with the ErbB ligand HRG also increased cell migration, via activation of both Erk5 and an Erb-
PTK6-Rac-p38 MAPK signaling pathway ((reviewed in Goel and Lukong 2015; Ostrander et al. 2007).  
PTK6’s interactions with the nuclear STAR (Signal Transduction and Activation of RNA) proteins 
(Sam68 and SLMs) and polypyrimidine tract-binding protein-associated splicing factor (PSF) are induced 
in response to EGF treatment. Phosphorylation of PSF and Sam68 (as well as the Sam68-like mammalian 
proteins, SLM1 and SLM2) by PTK6, results in inhibition of their RNA-binding activities. Reducing their 
RNA binding capability is one mechanism of reducing the function of proteins that bind RNA. As these 
proteins regulate a number of RNA processing events, including alternative splicing, PTK6 activation 
could result in the post-transcriptional regulation of gene expression. In addition EGF-mediated activation 
of PTK6 induced phosphorylation of Sam68 which increased cell proliferation. This presumably occurred 
through suppressing the anti-proliferative properties of Sam68 (Lukong et al, 2005; reviewed in Harvey 
and Burmi 2011). 
PTK6 expression has also been linked to the potential regulation of IGF signaling. PTK6 interacts with 
the IGF-1R/IRS-1 complex resulting in increased activation of IGF-1R, as well as Akt. An increase in 
IGF-1-mediated, anchorage-independent cell survival was also observed in both breast and ovarian cancer 
cells (Irie et al. 2010). Similar effects on cell survival have also been shown in serum stimulated breast 
cancer cells, where PTK6 again protected against cell death in suspension culture (Harvey et al. 2009). 
Interestingly, in both IGF-1 stimulated cells and lapatinib-resistant cells PTK6 protected cells from 
classical apoptosis/anoikis (Irie et al 2010; Park et al 2015), whereas the Harvey study showed that PTK6 
protected breast cancer cells from cell death via autophagy. Taken together, these studies indicate that 
PTK6 can protect cells from different types of programmed cell death, and that this protection is through 
different mechanisms. 
Furthermore, treatment of breast cancer cells with the Met receptor ligand, HGF, induced both activation 
of Erk5 and cell migration (Castro et al. 2010). The PTK6/Erk5 interaction and the increased migration 
that was induced in response to HGF was not dependent on the kinase activity of PTK6, providing further 
evidence that some aspects of PTK6 function are not reliant on its kinase domain. This implies that PTK6 
could coordinate the large signaling complexes that are required for cell migration, without directly 
phosphorylating components of the complex. 
Most of the PTK6-mediated interactions and activation events result in altered cell behaviors such as 
increased proliferation, cell survival, migration and the secretion of angiogenic factors, all of which are 
traits that are characteristic of tumor cells and are required for tumor development (Reviewed in Hanahan 
and Weinberg 2000). It would appear from the majority of studies carried out in tumor cell lines, that 
PTK6 could play a central role in tumor progression, especially in breast cancer. In support of this 
hypothesis Chakraborty and colleagues showed that treating cells with OPN resulted in PTK6 activation 
and an increase in vascular endothelial growth factor (VEGF) production. Combined with in vivo models, 
they were able to demonstrate that OPN triggers VEGF-dependent angiogenesis (formation of new blood 
vessels) and tumor growth as a result of PTK6 activation (Chakraborty et al. 2008).  
In cells where PTK6 is physiologically expressed i.e normal differentiating cells, the effects of PTK6 
activation are distinct to those seen in tumor cells. When keratinocytes (skin cells) are treated with 
calcium, PTK6 is transiently activated and cell differentiation is induced, in contrast to the proliferation or 
migration seen in tumor cells. Recent evidence suggests that PTK6, the EGF receptor (EGFR) and a 
marker of differentiation (involucrin), may be co-regulated during differentiation, and that the 
differentiation of normal primary human keratinocytes could be influenced by altered PTK6 expression 
(reviewed in Harvey and Burmi 2011; Goel and Lukong 2015). 
It is clear that PTK6 signaling is diverse (Figure 2), and that PTK6’s function with respect to signaling is 
different in normal differentiating cells to that in tumor progression. PTK6 has also been shown to 
associate directly with Akt (Zhang et al 2005) and, in conjunction with results from several other studies, 
has lead to the hypothesis that one of PTK6’s roles in normal cells could be to constrain Akt activation, 
possibly to allow differentiation to occur. In tumor cells, the constraint is lost and the PI3-K/Akt pathway 
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Figure 2: Potential biological effects of PTK6-mediated interactions.  
 
PTK6 Expression Profile 
PTK6 expression is increased in many tumors compared to normal epithelial cells (reviewed Harvey and 
Burmi 2011) and this is most notable and most well characterized in breast tissue. It is only recently that 
PTK6 expression was detected in normal breast cells (Peng et al. 2014), with previous studies 
demonstrating that up to 86% of breast cancers have elevated PTK6 expression and that the increase in 
expression correlated with an increase in tumor grade (reviewed Harvey and Burmi 2011). is mediated by 
several factors including NFB, Sp1, HIF1, and the glucocorticoid receptor and correlates with HER2 
overexpression and/or amplification in some tumors (reviewed in Goel and Lukong 2015;). This is 
important from a tumor development stand-point, as interaction of PTK6 protein with HER2 induces and 
prolongs the activation of the MAPK pathway which would result in increased cell cycle progression and 
tumor cell proliferation and, in mouse models, PTK6 expression promotes ErbB2-induced tumorigenesis 
(Peng et al. 2015).  
Whilst not the whole picture, and the clinical significance is currently far from clear, a number of studies 
have also reported molecular changes that could lead to elevated PTK6 expression (reviewed Harvey and 
Burmi 2011), regulation by microRNAs (Haines et al. 2016), as well as missense and truncating 
mutations that could affect PTK6 function (reviewed Goel and Lukong 2015). This suggests that there are 
multiple mechanisms contributing to PTK6’s overexpression. 
These findings, taken together alongside the current knowledge of PTK6’s multiple signaling roles in 
tumor cells, suggest that PTK6 is strongly implicated in tumor development. It could therefore be 
expected that PTK6 expression would have a negative impact on breast cancer patient survival and 
Kaplan-Meier survival analysis supports this conclusion (Pires et al. 2014).  
Summary 
There is little doubt that the role of PTK6 is complex. It depends on a number of factors including cellular 
localization, accessibility of binding partners, availability of extracellular signaling molecules and 
potentially, at least in tumor cells, the extent to which PTK6 expression is elevated. Further studies are 
fundamental to unraveling the complex and distinct roles that PTK6 plays in both normal differentiating 
cells and in tumor development. Progress in the isolation and development of compounds that inhibit 
PTK6’s kinase activity, along with recent elucidation of the crystal structure, are fundamental to 
furthering our understanding of the distinctions between a pro-differentiation role in normal cells, and a 
potentially oncogenic role in tumor progression; this is key to the development of novel therapeutic 
agents that could target either context-specific or cell-specific molecular functions and/or interactions 
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